Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Thorac Oncol. 2019 Aug 27;14(12):2152–2163. doi: 10.1016/j.jtho.2019.08.009

Figure 2.

Figure 2.

(A)B6129F1 immunocompetent mice bearing RPP tumors on their flank were treated with SRA737 (100mg/kg, 3/7 days or 5/7 days) and/or anti-PD-L1 (300μg, 1/7 days) (n = 10 per group). Tumor growth curves are shown as the mean tumor volume +/− standard error of the mean (SEM).

(B)Immunoblot analysis of tumors resected at Day 7 from a cohort of mice treated with vehicle, SRA737 (5/7), anti-PD-L1 or SRA737 (5/7) + anti-PD-L1. STING pathway activation was determined by immunoblotting for pSTING_S366, total STING, pTBK1_S172, total TBK1, cGAS, pIRF3_S396, and total IRF3.

(C) Quantitative PCR (qPCR) measurement of IFNβ, CXCL10 and CCL5 mRNA expression in SCLC tumors resected as described in B.

Data presented as mean ± SD and p values by t-test * p<0.05, **p<0.01, ***p<0.001.

HHS Vulnerability Disclosure